nach oben

Erschienen in:

2023 | OriginalPaper | Buchkapitel

6. Antipsychotika

verfasst von : Prof. Dr. med. Claudia Mehler-Wex, Prof. Dr. med. Timo D. Vloet, Prof. Dr. rer. nat. Manfred Gerlach

Erschienen in: Neuro-/Psychopharmaka im Kindes- und Jugendalter

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Antipsychotika (früherer Begriff Neuroleptika) sind Neuro‑/Psychopharmaka, die vorrangig zur symptomatischen Behandlung von Erkrankungen aus dem schizophrenen Formenkreis eingesetzt werden sowie bei psychotischen Symptomen im Rahmen anderer Störungen (u. a. affektive oder organisch bedingte Störungen) und bei Manie. Einige werden in der Kinder- und Jugendpsychiatrie aber auch als Stimmungsstabilisatoren, bei Tic-Störungen und zudem symptomatisch bei Reizbarkeit, Agitiertheit und aggressiven Verhaltensweisen sowie Anspannung, Einschlafstörungen oder gedanklicher Einengung angewandt.

In diesem Kapitel werden die Klassifikation und Wirk(ungs)mechanismen der Antipsychotika, die in der Kinder- und Jugendpsychiatrie eingesetzt werden, besprochen und schwerpunktmäßig diejenigen pharmakologischen Aspekte von Antipsychotika dargestellt, die für klinisch tätige ärztliche Kollegen für den therapeutischen Einsatz dieser Substanzen relevant sind. Dabei wird u. a. auf Anwendungsgebiete, die klinische Wirksamkeit und die Studienlage eingegangen. Es werden Dosierungsempfehlungen gegeben und mögliche unerwünschte Arzneimittelwirkungen und -wechselwirkungen behandelt. Das Kapitel schließt mit Empfehlungen zur Behandlungsdauer sowie zu notwendigen Kontrolluntersuchungen im Rahmen der Pharmakotherapie mit Antipsychotika.

AACAP Official Action (2001) Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Psy 40(Suppl):4–S23

Al-Dhaher Z, Kapoor S, Saito E et al. (2016) Activating and tranquilizing effects of first-time treatment with aripiprazole, olanzapine, quetiapine, and risperidone in youth. J Child Adolesc Psychopharmacology 26:458–470CrossRef

Aman MG, Mcdougle CJ, Scahill L et al. (2009) Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. J Am Acad Child Psy 48:1143–1154 (for the Research Units on Pediatric Psychopharmacology Autism Network)CrossRef

Amato D, Canneva F, Cumming P et al. (2020) A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter. Mol Psychiatry 25:2101–2118PubMedCrossRef

Amor LB (2012) Antipsychotics in pediatric and adolescent patients: a review of comparative safety data. J Affect Disorders 138:22–S30CrossRef

Ayanthi AR, Hickman IJ, Wang AYH et al. (2006) Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum. J Clin Psychopharm 26:232–237CrossRef

Bai YH, Liu TB, Xu AH, Yang HC, Gao KM (2019) Comparison of common side effects from mood stabilizers and antipsychotics between pediatric and adult patients with bipolar disorder: a systematic review of randomized, double-blind, placebo-controlled trials. Expert Opin Drug Safety 18:703–717CrossRef

Baptista T, Kin Y, Beaulieu S, de Baptista EA (2002) Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35:205–219PubMedCrossRef

Benes FM (2009) Neural circuitry models of schizophrenia: Is it dopamine, GABA, glutamate, or something else? Biol Psychiat 65:1003–1005PubMedCrossRef

Bernagie C, Danckaerts M, Wampers M, De Hert M (2016) Aripiprazole and acute extrapyramidal symptoms in children and adolescents: a meta-analysis. CNS Drugs 30:807–818PubMedPubMedCentralCrossRef

Brannan SK, Sawchak S, Miller AC et al. (2021) Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. New Engl J Med 384:717–726PubMedCrossRef

Brown AS (2011) The environment and susceptibility to schizophrenia. Prog Neurobiol 93:23–58PubMedCrossRef

Calarge CA, Burns TL, Schlechte JA, Zemel BS (2015) Longitudinal examination of the scelettal effects of selective serotonin reuptake inhibitors an risperidone in boys. J Clin Psychiatry 76:607–613PubMedPubMedCentralCrossRef

Campbell M, Small AM, Green WH et al. (1984) A comparison of haloperidol and lithium in hospitalized aggressive conduct disordered children. Arch Gen Psychiat 41:650–656PubMedCrossRef

Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140–144CrossRef

Carpenter WT, Davis JM (2012) Perspective. Another view of the history of antipsychotic drug discovery and development. Mol Psychiatr 17:1168–1173CrossRef

Ceraso A, Lin JJ, Schneider-Thoma J et al. (2020) Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 11:Cd8016

Chandradasa M, Ruwanpriya S, de Silva S, Rathnayake L, Kuruppuarachchi K (2022) Randomised, placebo-controlled trial on topiramate add-on therapy for weight reduction and symptomatology in overweight/obese persons with schizophrenia. Asian J Psychiatr 68:102963. https://doi.org/10.1016/j.ajp.2021.102963CrossRefPubMed

Chang C-Y, Luo D-Z, Pei J-C et al. (2021) Not just a bystander: The emerging role of astrozytes and research tools in studying cognitive dysfunctions in schizophrenia. Int J Mol Sci 22:5343. https://doi.org/10.3390/ijms22105343CrossRefPubMedPubMedCentral

Cohen D, Huinink S (2007) Atypical antipsychotic-induced diabetes mellitus in child and adolescent psychiatry. CNS Drugs 21:1035–1038PubMedCrossRef

Comai S, Tau M, Pavlovic Z, Gobbi G (2012) The psychopharmacology of aggressive behavior: a translational approach. Part 2: Clinical studies using atypical antipsychotics, anticonvulsants, and lithium. J Clin Psychopharm 32:237–260CrossRef

Correll CU (2008) Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Psy 47:9–20CrossRef

Correll CU (2011) Antipsychotic agents: traditional and atypical. In: Martin A, Scahill L, Kratochvil (Hrsg) Pediatric psychopharmacology. Principles and practise, 2. Aufl. University Press, Oxford New York, S 312–337

Correll Ch, Carlson HE (2006) Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Psy 45:771–791CrossRef

Correll CU, Kane JM (2007) One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol 17:647–655PubMedCrossRef

Correll CU, Sheridan EM, DelBello MP (2010) Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord 12:116–141PubMedCrossRef

Correll CU, Kratochvil CJ, March JS (2011) Development in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiat 72:655–670CrossRef

Correll CU, Kohegy E, Zhao C (2017) Oral aripiprazole as maintenance treatment in adolsescent schizophrenia: results from a 52-week, randomized, placebo-controlles withdrawal study. J Am Acad Child Adolesc Psychiatry 56:784–792PubMedCrossRef

Correll CU, Litman RE, Filts Y et al. (2020a) Efficacy and safety of once monthly Risperidone ISM in schizophrenic patients with acute exacerbation. Schizophrenia 6:37PubMedPubMedCentralCrossRef

Correll CU, Sikich L, Reeves G et al. (2020b) Metformin add-on vs. Antipsychotic switch vs. Continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. World Psychiatry 19:69–80PubMedPubMedCentralCrossRef

Coustals N, Ménard ML, Cohen D (2020) Aripiprazole in children and adolescents. J Child Adolesc Psychopharmacol 20:1–29

Creese I, Burt DR, Snyder SH (1976) Dopamine receptors binding predicts clinical potencies of antischizophrenic drugs. Science 192:481–483PubMedCrossRef

DeNayer A, DeHert M, Scheen A, Van Gaal L, Peuskens J (2007) Belgian consensus on metabolic problems associated with atypical antipsychotics. Encephale 33:197–202CrossRef

DelBello MP, Goldman R, Philips D et al. (2017) Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double-blind, placebo controlled study. J Am Acad Child Adolesc Psychiatry 56:1015–1025PubMedCrossRef

Dietmaier O, Laux G (2020) Weiterbildungs-Curriculum Pschopharmakologie/Pharmakotherapie. Teil 15: Kombinationstherapien, Interaktionen. Psychopharmakotherapie 27:295–305

Ebdrup BH, Knop FK (2021) Weight gain on antipsychotics - A perfect storm of complex pathophysiology and psychopharmacology. Acta Psychiatr Scand 144:521–523PubMedCrossRef

Egberts K, Mehler-Wex C, Gerlach M (2011) Therapeutic drug monitoring in child and adolescent psychiatry. Pharmacopsychiatry 44:249–253PubMedCrossRef

Eggers C, Roepcke B (2007) Schizophrenie, schizotype und wahnhafte Störungen (F2). In: Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie, Bundesarbeitsgemeinschaft Leitender Klinikärzte für Kinder- und Jugendpsychiatrie, Psychotherapie und Bundesverband der Ärzte für Kinder- und Jugendpsychiatrie und Psychotherapie (Hrsg) Leitlinien zu Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter, 3. Aufl. Deutscher Ärzte-Verlag, Köln, S 33–43

Eggers C, Rothenberger A, Berghaus U (1988) Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psy Clin N 237:223–229

Ellul P, Delorme R, Cortese S (2018) Metformin for weight gain associated with second generation antipsychotics in children and adolescents: a systematic review and meta-analysis. CNS Drugs 32:1103–1112PubMedCrossRef

FDA (2016) FDA warns about rare but serious skin reactions with mental health drug olanzapine. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-rare-serious-skin-reactions-mental-health-drug (Erstellt: 10. Mai 2016)

Findling RK, Cavus I, Pappadopulos E et al.(2013) Ziprasidone in adolescents with schizophrenia: Results from a placebo-controlled efficacy and long-term open-extension study. J Child Adoles Psychopharmacol 23:531-544CrossRef

Findling RL, Landbloom RP, Mackle M et al. (2015a) Safety and efficacy from an 8 week double-blind trial and a 26 week open label extension of asenapine in children and adolescents with schizophrenia. J Child Adolesc Psychopharmacol 25:384–396PubMedPubMedCentralCrossRef

Findling RL, Landbloom RL, Szegedi et al. (2015b) Asenapine for the acute treatment of pediatric manic or mixed episode of bipolar I disorder. J Am Acad Child Adolesc Psychiatry 54:1032–1041PubMedCrossRef

Fleischhaker Ch, Heiser P, Hennighausen K et al. (2008) Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. J Neural Transm 115:1599–1608PubMedCrossRef

Fountoulakis KN, Moeller HJ, Kasper S et al. (2021) The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. CNS Spectr 26:562–586CrossRef

Fraguas D, Correll CU, Merchán-Naranjo J et al. (2011) Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharm 21:621–645CrossRef

Friedrich ME, Winkler D, Konstantinidis A et al. (2020) Cardiovascular adverse reactions during antipsychotic treatment: results of AMSP, a drug surveillance program between 1993 and 2013. Int J Psychopharmacol 23:67–75

Galling B, Roldán A, Nielsen RE et al. (2016) Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry 73:247–259PubMedCrossRef

Galling B, Roldán A, Hagi K et al. (2017) Antipsychotic augementation versus monotherapy in schiziphrenia: a systematic review, meta-analysis und meta-regression analysis. World Psychiatry 16:77–89PubMedPubMedCentralCrossRef

Gebicke-Haerter PJ (2012) Epigenetics of schizophrenia. Pharmacopsychiatry 45(Suppl 1):S42–S48PubMed

Gerlach M (2021) Pharmakologische und rechtliche Grundkenntnisse der Psychopharmakotherapie. Psych Up2date 15:71–84CrossRef

Gerlach M, Hünnerkopf R, Rothenhöfer S et al. (2007) Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry 40:72–76PubMedCrossRef

Giessing Jensen K, Juul K, Fink-Jensen A, Correll CU (2015) Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychaitry 54:25–36CrossRef

Glassman AH, Bigger Th (2001) Antipsychotic drugs: Prolonged QTc interval, torsade de pointes and sudden death. Am J Psychiat 158:1774–1782PubMedCrossRef

Goedhard LE, Stolker JJ, Herrdink ER et al. (2006) Pharmacotherapy of aggressive behavior in general adult psychiatry: A systematic review. J Clin Psychiat 67:1013–1024CrossRef

Goldman R, Loebel A, Cucchiaro J (2017) Efficacy and safety of lurasidone in adolescents with schizophrenia: a six-week, randomized placebo controlled study. J Child Adolesc Psychopharmacol 27:516–525PubMedPubMedCentralCrossRef

Goldstein BI, Sassi R, Diler RS (2012) Pharmacological treatment of bipolar disorder in children and adolescents. Child Adolesc Psychiatr Clin N 21:911–939CrossRef

Grohmann R, Hippius H, Rüther R (2001) Extrapyramidal motor side-effects and blood profile changes. Stumbling blocks in psychiatric pharmacotherapy. MMW Fortschr Med 77(Suppl 2):76–77

Guber KM, Cortes ND, Duan L (2021) Risk of obesity among children prescribes atypical antipsychotics for six months or more. J Child Adolesc Psychiatry. https://doi.org/10.1089/cap.2021.0021CrossRef

Guinart D, Taipale H, Rubio JM et al. (2021) Risk Factors, incidence, and outcomes of neuroleptic malignant syndrome on long-acting injectable vs oral antipsychotics in a nationwide schizophrenia cohort. Schizophr Bull 476:1621–1623CrossRef

Haase HJ (1954) About prevalence and interpretation of the psychomotor Parkinson syndrome in megaphen or largactil treatment duration. Nervenarzt 25:486–492PubMed

Haase HJ, Janssen PAJ (1965) The action of neuroleptic drugs. Year Book Medical, Chicago

Hasan A, Falkai P, Wobrock T et al. (2015) World Federation of Societis of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 3: update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry 16:142–170 (on behalf of the WFSBP Task Force on Treatment Guidelines for Schizophrenia)PubMedCrossRef

Häßler F, Dück A, Jung M, Reis O (2014) treatment of aggressive behavior problems in boys with intellectual disabilities using zuclopenthixol. J Child Adolesc Psychopharmacol 24:579–581PubMedCrossRef

Heck J, Krichewsky B, Krause O et al. (2021) Photosensibilisierung durch Psychopharmaka und andere Arzneimittel. Psychopharmakotherapie 28:94–101

Henderson DC, Cagliero E, Copeland PM et al. (2007) Elevated hemoglobin A1c as possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atipycal antipsychotics. J Clin Psychiat 68:533–541CrossRef

Hiemke C, Pfuhlmann B (2012) Interactions and monitoring of antipsychotic drugs. Handb Exp Pharmacol 212:241–265CrossRef

Hiemke C, Bergemann N, Clement HW et al. (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology - Update 2017. Pharmacopsychiatry 51:9–62PubMedCrossRef

Højlund M, Kemp AF, Haddad PM et al. (2021) Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Lancet Psychiatry 8:471–486PubMedCrossRef

Howes O, McCutcheon R, Stone J (2015) Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol 29:97–115PubMedPubMedCentralCrossRef

Howes OD, McCutcheon R, Owen MJ, Murray RM (2017) The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry 81:9–20PubMedCrossRef

Huber M, Schlosser-Weber G, Paeschke N, Broich K (2015) Antipsychotika in der Schwangerschaft. Psychopharmakotherapie 22:278–285

Huhn M, Nikolakopoulou A, Schneider-Thoma J et al. (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394:939–951PubMedPubMedCentralCrossRef

Huybrechts KF, Hernandez-Diaz S, Patorno E et al. (2016) Antipsychotic use in pregnancy and the risk of congenital malformations. JAMA Psychiatry 73:938–946PubMedPubMedCentralCrossRef

Jensen KG, Juul K, Fink-Jensen A, Correll CU, Pagsberg AK (2015) Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychiatry 54:25–36PubMedCrossRef

Kaar SJ, Natesan S, McCutcheon R, Howes OD (2020) Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2019.107704CrossRefPubMed

Kapur S, Seeman P (2000) Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatr Neurosci 25:161–166

Kapur S, Seeman P (2001) Does fast dissociation from the dopamine D2 receptor explaine the action of atypical antipsychotics? A new hypothesis. Am J Psychiat 158:360–369PubMedCrossRef

Keefe RSE, Bilder RM, Davis SM et al. (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiat 64:633–647 (CATIE investigators and the Neurocognitive Working Group)PubMedCrossRef

Kegeles LS, Slifstein M, Frankle WG et al. (2008) Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [¹⁸F]fallypride. Neuropsychopharmacology 33:3111–3125PubMedCrossRef

Keks N, Hope J, Schwartz D et al. (2020) Comparative tolerability of dopamine D2/3 receptor partial agonists for schizophrenia. CNS Drugs 34:473–450PubMedCrossRef

Kennedy WK, Jann MW, Kutscher EC (2013) Clinically significant drug interactions with atypical antipsychotics. CNS Drugs 27:1021–1048PubMedCrossRef

Khandaker GM, Zimbron J, Dalman C, Lewis G, Jones PB (2012) Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. Schizophr Res 139:161–168PubMedPubMedCentralCrossRef

Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU (2019) Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-tohead comparisons. World Psychiatry 18:208–224PubMedPubMedCentralCrossRef

Klampfl K, Taurines R, Preuss A et al. (2010) Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy. Pharmacopsychiatry 43:58–65PubMedCrossRef

Koblan KS, Kent J, Hopkins SC et al. (2020) A non-D2-receptor-binding drug for the treatment of schizophrenia. New Engl J Med 382:1497–1506PubMedCrossRef

Köster L-S, Carbon M, Correll CU (2014) Emerging drugs for schizophrenia: an update. Expert Opin Emerg Drugs 19:511–531PubMedCrossRef

Koller E, Schneider B, Bennett K, Dubitsky G (2001) Clozapine-associated diabetes. Am J Med 111:716–723PubMedCrossRef

Koller EA, Cross JT, Schneider B (2004a) Risperidone-associated diabetis mellitus in children. Pediatrics 113:421–422PubMedCrossRef

Koller EA, Weber J, Doraiswamy PM, Schneider BS (2004b) A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiat 65:857–863CrossRef

Kornhuber J, Thome J, Riederer P (1998) Modellvorstellungen zur Ätiopathogenese der Schizphrenien. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuroleptika, 2. Aufl. Neuro-Psychopharmaka. Ein Therapie-Handbuch, Bd. 4. Springer, Wien, S 3–21

Koskuvi M, Lehtonen S, Trontti K et al. (2022) Contribution of astrocytes and clinical manifestation of schizophrenia. Glia 70:650–660PubMedCrossRef

Kulkarni SK, Naidu PS (2003) Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drug Today 39:19–49CrossRef

Labad J, Montalvo I, Gonzalez-Rodriguez A et al. (2020) Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinemia: a systematic review and meta-analysis. Schizophr Res 222:88–96PubMedCrossRef

Laruelle M (2014) Schizophrenia: from dopaminergic to glutamatergic interventions. Curr Opin Pharmacol 14:97–102PubMedCrossRef

Lee SE, Kronsberg H, Findling RL (2020) Psychopharmacologic treatment of schizophrenia in adolsecents and children. Child Adolesc Psychiatr Clin N Am 29:183–210PubMedCrossRef

Lessig MC, Shapira NA, Murphy TK (2001) Topiramate reversing atypical antipsychotic weight gain. Letter J Am Acad Child Psy 40:1364CrossRef

Leucht S, Corves C, Arbter D et al. (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41PubMedCrossRef

Li A, Zalesky A, Yue W et al. (2020) A neuroimaging biomarker for striatal dysfunction in schizophrenie. Nat Med 26:558-565PubMedCrossRef

Libowitz MR, Nurmi EL (2021) The burden of antipsychotic-induced weight gain and metabolic syndrome in children. Front Psychiatry 12:623681 https://doi.org/10.3389/fpsyt.2021.623681CrossRefPubMedPubMedCentral

Lieberman JA (2004) Dopamine partial agonists. A new class of antipsychotics. CNS Drugs 18:251–267PubMedCrossRef

Liu HY, Potter MP, Woodworth KY et al. (2011) Pharmcologic treatments for pediatric bipolar disorder: a review and meta-analysis. J Am Acad Child Psy 50:749–762CrossRef

Loebel A, Brams M, Goldman R et al. (2016) Lurasidone for the treatment of irritability associated with autistic disorder. J Autism Dev Disord 46:1153–1163PubMedCrossRef

López-Muñoz F, Alamo C, Cuenca E et al. (2005) History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry 17:113–135PubMedCrossRef

Madaan V, Dvir Y, Wilson DR (2008) Child and adolescent schizophrenia: pharmacological approaches. Exp Opin Pharmacol 9:2053–2068CrossRef

Man KKC, Shao SC, Chang YC et al. (2021) Cardiovascular and metabolic risk of antipsychotics in children and young adults: A multinational self-controlled case series study. Epidem Psychiatr Sci 30:e65. https://doi.org/10.1017/s2045796021000494CrossRef

Marenco S, Weinberger DR (2000) The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev Psychopathol 12:501–527PubMedCrossRef

Martin WF, Correll CU, Weiden PJ et al. (2019) Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia. Am J Psychiatry 176:457–467PubMedCrossRef

Masi G, Liboni F (2011) Management of schizophrenia in children and adolescents. Drugs 71:179–208PubMedCrossRef

McCutcheon RA, Abi-Dargham A, Howes OD (2019) Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci 42:205–220PubMedPubMedCentralCrossRef

Mishara AL, Goldberg TE (2004) A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: Opening a closed book. Biol Psychiat 55:1013–1022PubMedCrossRef

Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79–104PubMedCrossRef

Möller HJ, Müller WE, Bandelow B (2001) Neuroleptika. Pharmakologische Grundlagen, klinisches Wissen und therapeutisches Vorgehen. Wissenschaftliche Verlagsgesellschaft, Stuttgart, S 243

Müller WE (2019) Vergleichende Betrachtung der pharmakologischen Eigenschaften von Dopamin-D2-Partialagonisten. Psychopharmakotherapie 26:192–204

Munawar N, Ahsan K, Muhammad K et al. (2021) Hidden role of gut microbiome dysbiosis in schizophrenia: antipsychotics or psychobiotics as therapeutics? Int J Mol Sci 22:7671. https://doi.org/10.3390/ijms22147671CrossRefPubMedPubMedCentral

Morrison JA, Cottingham EM, Barton BA (2002) Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiat 159:655–657PubMedCrossRef

Naguy A, Adel T, Almazeedi I (2019) Paliperidone use in child psychiatry: evidence or diffidence? Pharmacology 104:67–70PubMedCrossRef

Nevels RM, Dehon EE, Alexander K, Gontkovsky ST (2010) Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: A review of current and potentially promising treatment options. Exp Clin Psychopharm 18:184–201CrossRef

Onishi Y, Mikami K, Kimoto K et al. (2021) Second-generation antipsychotic drugs for children and adolescents. Review. J Nippon Med Sch 88:10–16PubMedCrossRef

Pagsberg AK, Tarp S, Glintborg D et al. (2017) Acute antipsychotic treatment with schizophrenia spectrum disorders: a systematic review and network meta-analysis. J Am Acad Child Adolesc Psychiatry 56:191–202PubMedCrossRef

Patteet L, Morrens M, Maudens KE et al. (2012) Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit 34:629–651PubMedCrossRef

Pillay J, Boylan K, Newton A et al. (2018) Harms of antipsychotics in children and adolescents: a systematic review update. Can J Psychiatry 63:661–678PubMedPubMedCentralCrossRef

Pozzi M, Ferrentino RI, Scrinzi C et al. (2020) Weight and body mass index increase in children and adolescents exposed to antipsychotic drugs in non-interventional settings: a meta-analysis and meta-regression. Eur J Child Adolesc Psychiatry. https://doi.org/10.1007/s00787-020-01582-9CrossRef

Pringsheim T, Gorman D (2012) Second-generation antipsychotics for the treatment of disruptive behaviour disorders in children: a systematic review. Can J Psychiat 57:722–727CrossRef

Pringsheim T, Lam D, Ching H, Patten S (2011) Metabolic and neurological complications of second-generation anti-psychotic use in children. Drug Saf 34:651–668PubMedCrossRef

Rahman T, Sahrmann JM, Olsen MA et al. (2022) Risk of breast cancer with prolactin elevating antipsychotic drugs: an observational study of US women (Ages 18-64 years). J Clin Psychopharmacol 42:7–16PubMedPubMedCentralCrossRef

Razjouyan K, Danesh A, Khademi M, Davari-Ashtiani R, Noorbaksh S (2018) A comparative study of risperidone and aripiprazole in attention deficit hyperactivity disorder in children under six years old. A randomized double-blind study. Iran J Pediatr 28:e60087CrossRef

Remington G, Hahn MK, Agarwal SM, Chintoh A (2021) Schizophrenia: Antipsychotics and drug development. Behav Brain Res 414:113507. https://doi.org/10.1016/j.bbr.2021.113507CrossRefPubMed

Reyad AA, Mishriky R (2019) Asenapine: Pharmacological aspects and role in psychiatric disorders. Psychiatr Danube 31:157–161CrossRef

Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M (2006) A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiat 163:402–410PubMedCrossRef

Robb AS, Carson WH, Nyilas M et al. (2010) Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: Post-hoc analysis of randomized clinical trial data. J Child Adol Psychop 20:33–38CrossRef

Sallee F, Kohegy E, Zhao J et al. (2017) Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole fort he treatment of Tourette’s disorder in children and adolescents. J Child Adolesc Psychopharmacol 27:771–781PubMedPubMedCentralCrossRef

Sallee FR, Kurlan R, Goetz CG et al. (2000) Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Psy 39:292–299CrossRef

Scahill L, Lechman JF, Schultz RT, Katsovich L, Peterson BS (2003) A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 60:1130–1135PubMedCrossRef

Schatzberg AF, Cole JO, De Battista C (2003) Manual of clinical psychopharmacology, 4. Aufl. American Psychiatric Publishing, Washington

Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU (2013) Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Curr Opin Psychiatr 26:219–230CrossRef

Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature 511:421–427PubMedCentralCrossRef

Seeman MV (2021) History of the dopamine hypetric Dothesis of antipsychotic action. World J Psychiatr 11:355–364PubMedPubMedCentralCrossRef

Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiat 47:27–38CrossRef

Seeman P, Lee T (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217–1219PubMedCrossRef

Seida JC, Schouten JR, Boylan K et al. (2012) Antipsychotics for children and youth adults: A comparative effectiveness review. Pediatrics 129:e771–e784PubMedCrossRef

Shao P, Ou JJ, Peng M et al. (2015) Effects of clozapine and other atypical antipsychotics on infants development who were exposed to as fetus: a post-hoc analysis. Plos One 10:4 (Article Nr. e0123373)

Shapiro M, Reid A, Olsen B (2016) Topiramate and zonisamide and weight loss in children and adolscents prescribed psychiatric medications. Int J Psychiatry Med 51:56–68PubMedCrossRef

Siafis S, Wu H, Wang DF et al. (2023) Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Mol Psychiatry. https://doi.org/10.1038/s41380-023-02203-yCrossRefPubMedPubMedCentral

Silva RR, Munoz DM, Alpert M, Perlmutter IR, Diaz J (1999) Neuroleptic malignant syndrome in children and adolescents. J Am Acad Child Psy 38:187–194CrossRef

Singappuli P, Sonuga-Barke E, Kyriakopoulos M (2021) Antipsychotic long-term treatment in children und young people: a systematic review and meta-analysis of efficacy and tolerability across mental health and neurodevelopmental conditions. CNS Spectr. https://doi.org/10.1017/s1092852921000523CrossRefPubMed

Singh J, Robb A, Vijapurkar U, Nuamah I, Hough D (2011) A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry 70:1179–1188PubMedCrossRef

Smith RC, Maayan L, Wu R et al. (2018) Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study. Psychopharmacology 235:3545–3558PubMedCrossRef

Solmi M, Pigato G, Kane JM, Correll CU (2018) Clinical risk factors for the development of tardive dyskinesia. J Neurol Sciences 389:21–27CrossRef

Spencer EK, Kafantaris V, Padron-Gayol MV, Rosenberg CR (1992) Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacol Bull 28:183–186PubMed

Stentjeberg-Olesen M, Ganocy S, Findling R et al. (2015) Early response or non-response at week 2 and week 3 predict ultimate response or non-response in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. Eur Child Adolesc Psychiatry 24:1485–1496CrossRef

Stigler KA, Potenza MN, Posey DJ, McDougle CJ (2004) Weight gain associated with atypical antipsychotic use in children and adolescents. Prevalence, clinical relevance, and management. Pediatr Drugs 6:33–44CrossRef

Szatmari B, Barabassy A, Harsanyi J et al. (2020) Cariprazine safety in adolescents and the elderly: analysis of clinical study data. Front Psychiatry 11:61. https://doi.org/10.3389/fpsyt.2020.00061CrossRefPubMedPubMedCentral

S3-Leitlinie Schizophrenie (2019) https://www.awmf.org/uploads/tx_szleitlinien/038-009k_S3_Schizophrenie_2019-03.pdf

Tamminga CA (2006) Principles of pharmacology of schizophrenia. In: Charney DS, Nestler (Hrsg) Neurobiology of mental illnesses, 2. Aufl. Oxford University Press, Oxford, S 339–354

Tickell AM, Rohleder C, Ho NI et al. (2021) Identifying pathways to early-onset metabolic dysfunction, insulin resistance and inflammation in young adult inpatients with emerging affective and major mood disorders. Early Interv Psychiatry 16:1121–1129PubMedCrossRef

Vancampfort D, Firth J, Correll CU et al. (2019) The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of Metaanalyses of randomized controlled trials. World Psychiatry 18:53–66PubMedPubMedCentralCrossRef

Vazquez-Bourgon J, Alario MI, Mayoral van Son J et al. (2020) A 3-year prospective study on the metabolic effect of aripiprazol, quetiapin and ziprasidone: a pragmatic clinical trial in first episode psychosis patients. Eur Neuropsychopharmacol 39:46–55PubMedCrossRef

Vieta E, Montes E (2018) A review of asenapine in the treatment of bipolar disorder. Clin Drug Invest 38:87–99CrossRef

Wagner E, Hasan A (2018) Cariprazin – eine neue medikamentöse Therapieoption in der Schizophreniebehandlung. Psychopharmakotherapie 25:278–285

Weizman S, Shelef A, Bris EB, Stryjer R (2021) A double-blind, placebo-controlled trial of bupropion add-on to olanzapine in overweight individuals with schizophrenia. J Clin Psychopharmacology 41:629-631CrossRef

Wolkin A, Barouche F, Wolf A et al. (1989) Dopamine blockade and clinical response for two biological subgroups of schizophrenia. Am J Psychiatry 146:905–908PubMedCrossRef

Wu QQ, Huang J, Wu RR (2021) Drugs based on NMDAR hypofunction hypothesis in schizophrenia. Front Neurosci 15:641047. https://doi.org/10.3389/fnins.2021.641047CrossRefPubMedPubMedCentral

Yee CS, Bahji A, Lolich M, Vazquez GH, Baldessarini RJ (2022) Comparative efficacy and tolerability of antipsychotics for juvenile psychotic disorders: a systematic review and network meta-analysis. J Clin Psychopharmacol 42:198–208PubMedCrossRef

Zhao MJ, Qin B, Wang JB et al. (2018) Efficacy and acceptibility of cariprazine in acute exacerbation schizophrenia meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol 38:55-59PubMedCrossRef

Zuddas A, Zanni R, Usala T (2011) Second generation antipsychotics (SGas) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharm 21:600–620CrossRef

Howes OD, McCutcheon R, Owen MJ, Murray RM (2017) The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry 81:9–20PubMedCrossRef

S3-Leitlinie Schizophrenie (2019) https://www.awmf.org/uploads/tx_szleitlinien/038-009k_S3_Schizophrenie_2019-03.pdf

Titel: Antipsychotika
verfasst von: Prof. Dr. med. Claudia Mehler-Wex
Prof. Dr. med. Timo D. Vloet
Prof. Dr. rer. nat. Manfred Gerlach
Verlag: Springer Berlin Heidelberg
Buch: Neuro-/Psychopharmaka im Kindes- und Jugendalter
Print ISBN: 978-3-662-65266-4

Electronic ISBN: 978-3-662-65267-1

Copyright-Jahr: 2023
DOI: https://doi.org/10.1007/978-3-662-65267-1_6

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).